Study Title
M20-429: A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms
Protocol ID
M20-429
Condition/s
Non-Hodgkin Lymphoma
Diagnosis Stage
Relapsed/refractory
Location
NSW, VIC, WA
Sponsor
AbbVie
Collaborators
Genmab
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
Perth Children's Hospital
Royal Children's Hospital
Perth Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 Year to 21 Year5
International registry ID's
NCT05206357
| Study Title | M20-429: A Single Arm Open-Label Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms |
|---|---|
| Protocol ID | M20-429 |
| Disease (Sub Disease) | Non-Hodgkin Lymphoma |
| Diagnosis Stage | Relapsed/refractory |
| Location | NSW / VIC / WA |
| Sponsor | AbbVie |
| Collaborators | Genmab |
| Links | https://clinicaltrials.gov/ct2/show/NCT05206357 |
| Trial Status | Open |
| Trial Open Date | 29/09/2022 |
| Sites | The Children's Hospital at Westmead / Perth Children's Hospital / Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 1 Year to 21 Year5 |
| International registry ID's | NCT05206357 |